Feature | Artificial Intelligence | October 22, 2018 | By Greg Freiherr

WEB EXCLUSIVE: Smart Machines To Empower Oncology Docs and Patients, Say ASTRO Experts

This is the second web exclusive article in a series from Consulting Editor Greg Freiherr, reporting live from the show floor at ASTRO 2018

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

“AI is going to do the things that a machine can do better, and by offloading tasks (from people), it will enable us to do the more exciting stuff that we really need people for,” said Kristy K. Brock, Ph.D., a professor of imaging physics at The University of Texas MD Anderson Cancer Center in Houston. “We will be able to do the interpretations and (what) drives science forward — rather than checking the numbers that you would put into the computer.”

Machines cannot satisfy the inherently human function of physicians in health care; they cannot interact adequately with patients, said Andre Dekker, Ph.D., who followed Brock on stage at the ASTRO symposium. But artificial intelligence can provide the tools that will make this interaction more beneficial, he told a standing-room-only crowd of hundreds who attended the talks about AI.

“AI will allow us to share decision-making,” said Dekker, medical physicist and head of knowledge engineering at the MAASTRO clinic and professor at Maastricht University in Maastricht, The Netherlands. “We will be able to ask: ‘If treatments A to Z have these predicted outcomes, what fits you best? Is the toxicity worth it? Is the benefit worth it?’ ”

Consumer acceptance of AI is paving the way for this technology to have an increasingly important impact on the practice of medicine, Brock said.  AI is part of the public’s collective imagination from Amazon.com’s Alexa responding to requests from consumers to order more detergent to a predicted future of driverless cars.

In radiation oncology, artificial intelligence will be an enabling technology, she predicted, “not a robot-replacing-human technology.” It will enable radiation oncologists to generate the optimal patient information for the lowest risk in imaging, as well as intervention, Brock said.  It will allow the tumor burden to be accurately identified; the risk to be stratified; and the treatment to be planned.

 

First Impact

The availability of data used to train and validate smart algorithms will be an important limiting factor, however, in when and how AI will be applied in radiation oncology, Dekker said. Its availability will depend on overcoming barriers to sharing data, he said. Several factors may result in these barriers.

One is rooted in human nature.  People simply may not want to share the data they have gathered, he said. Or they may lack the resources to share the data. Or they may be prevented from sharing data by language differences. 

But, just as AI applications require the availability of data, so might AI fuel the applications to overcome these barriers. Such applications might automate the “mining” of clinical data, thereby reducing the time and cost of gathering data, just as they might translate data from one language to another, Dekker said.

 

Empowering Patients

Big data, crunched by smart algorithms, may eventually paint scenarios of how patients will fare with different treatment options, he said. In the future, he opined, smart machines might calculate the odds that different treatment options will have certain effects and toxicities; physicians might explain those options; and patients might choose which is best for them.  One treatment, for example, might offer longer survival, but be accompanied by the risk of greater toxicity and complications. Another might come with shorter survival, but less risk of toxicity and complications.  

“Will AI in the future allow us to precisely determine what will be the best treatment with the lowest toxicity and to understand these risks and benefits?” Brock asked. “Will we be able to translate this plan to the best plan that can be delivered?”

The optimization of patient outcomes will result, if AI is applied to improve processes in radiation oncology, according to Dekker. This will happen because the improvement of processes necessarily improves patient outcomes.

Ultimately AI will be a winning proposition for both patients and physicians. “You will have this ‘citizen science component,’” he said.  “It won’t mean that doctors are not necessary anymore.” 

 

For additional ASTRO information, see “WEB EXCLUSIVE: Market for MRI-based RT Could Soon Widen.”

Related Content

Table 1. Compared to 2-D mammography, which yields four images per patient, digital breast tomosynthesis (DBT), or 3-D mammography, produces hundreds of images per patient. While this provides more information for clinicians, the exponential increase in data can result in reader fatigue and burnout, which may ultimately affect patient care.

Table 1. Compared to 2-D mammography, which yields four images per patient, digital breast tomosynthesis (DBT), or 3-D mammography, produces hundreds of images per patient. While this provides more information for clinicians, the exponential increase in data can result in reader fatigue and burnout, which may ultimately affect patient care.

Sponsored Content | Case Study | Artificial Intelligence | April 09, 2020
As the largest independent imaging group in Michigan with 10 locations across the state,...
The interior of the German air force Airbus A-310 Medivac in Cologne, Germany, before its departure to Bergamo, Italy, March 28 to being ferrying COVID-19 patients to Germany for treatment to aid the Italians, whose healthcare system has been overwhelmed by the rapid spread of the coronavirus pandemic. Bundeswehr Photo by Kevin Schrief.

The interior of the German air force Airbus A-310 Medivac in Cologne, Germany, before its departure to Bergamo, Italy, March 28 to being ferrying COVID-19 patients to Germany for treatment to aid the Italians, whose healthcare system has been overwhelmed by the rapid spread of the coronavirus pandemic. Bundeswehr Photo by Kevin Schrief. Find more images from the COVID-19 pandemic.

 

Feature | Coronavirus (COVID-19) | April 08, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
A recent study earlier this year in the journal Nature, which included researchers from Google Health London, demonstrated that artificial intelligence (AI) technology outperformed radiologists in diagnosing breast cancer on mammograms
Feature | Breast Imaging | April 06, 2020 | By Samir Parikh
A recent study earlier this year in the journal Nature,
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 the company is now offering a suite of AI solutions Vuno Med-LungQuant and Vuno Med-Chest X-ray for COVID-19, encompassing both lung X-ray and computed tomography (CT) modalities respectively all at once
News | Artificial Intelligence | April 02, 2020
April 2, 2020 — In the face of the COVID-19 pand